PsyRx reports promising ibogaine study results

PsyRx's preclinical study on ibogaine and depression

PsyRx, an Israeli biotechnology company, has released promising findings from a preclinical study examining the effects of ibogaine, a psychoactive compound, in combination with citalopram, a common antidepressant. The study, conducted on October 21, 2026, involved 105 mice and aimed to explore new therapeutic avenues for depression and anxiety.

What the study found

According to PsyRx, the study divided the mice into seven groups to test various dosages of ibogaine, citalopram, and their combination. The results showed statistical significance in one anxiety-related measure when ibogaine was used as an adjunct to citalopram. Additionally, some measures indicated numerical improvements in the group receiving low-dose ibogaine with citalopram, though these did not reach statistical significance.

Regulatory context

The study's findings are preliminary and based on animal models, which means they do not yet establish the treatment's efficacy or safety in humans. PsyRx emphasizes the need for further research to evaluate the potential therapeutic significance of these results.

Why it matters

The study is part of PsyRx's broader effort to develop innovative mental health treatments that combine psychedelic compounds with existing antidepressants. This approach could potentially shorten the time to therapeutic effect and offer new solutions for treatment-resistant depression and PTSD. The research underscores the importance of exploring novel treatment combinations in the ongoing search for effective mental health therapies.

PsyRx's commitment to advancing mental health research highlights the potential of psychedelic compounds in modern medicine.